| Chronic Kidney Disease |
1 |
1 |
| Renal Failure |
0 |
0.9 |
| Renal Disease |
0 |
0.63 |
| Polycystic Kidney Disease |
0 |
0.52 |
| Hypertension |
0 |
0.5 |
| Cardiovascular disease |
0 |
0.42 |
| Receptors |
0 |
0.42 |
| Angiotensin II Receptor Blockade |
0 |
0.37 |
| Cardiovascular Risk Management |
0 |
0.36 |
| Food and Drug Administration (FDA) |
0 |
0.31 |
| Hyperkalemia |
0 |
0.31 |
| Europe |
0 |
0.21 |
| Washington |
0 |
0.21 |
| Type 2 Diabetes Mellitus |
0 |
0.15 |
| ACE Inhibitor |
0 |
0.1 |
| Brachial |
0 |
0.1 |
| Dialysis |
0 |
0.1 |
| Dorsum |
0 |
0.1 |
| Heart |
0 |
0.1 |
| Renin-Angiotensin System (RAS) |
0 |
0.1 |
| Third Space |
0 |
0.1 |
| Transplantation |
0 |
0.1 |
| Hemodialysis |
0 |
0.08 |